(Q46474880)

22 December 2017

title

PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer (English)

1 reference

22 December 2017

1 reference

4

1 reference

22 December 2017

author name string

David Robinson

1

1 reference

22 December 2017

Gabriel Sandblom

2

1 reference

22 December 2017

Robert Johansson

3

1 reference

22 December 2017

Gunnar Aus

5

1 reference

22 December 2017

Per Olov Hedlund

6

1 reference

22 December 2017

Eberhard Varenhorst

7

1 reference

22 December 2017

Scandinavian Prostate Cancer Group

8

1 reference

22 December 2017

language of work or name

English

0 references

publication date

17 July 2008

1 reference

22 December 2017

published in

Urology

1 reference

22 December 2017

volume

72

1 reference

22 December 2017

issue

4

1 reference

22 December 2017

page(s)

903-907

1 reference

22 December 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Metastatic Carcinoma of the Prostate: Identifying Prognostic Groups Using Recursive Partitioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

Role of nomograms for prostate cancer in 2007.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.05.026

10.1016/J.UROLOGY.2008.05.026

7 January 2021

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017